Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Publikation

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Wissenschaftlicher Artikel/Review - 05.02.2015

Amstutz Ursula, Offer Steven M, Sistonen Johanna, Joerger Markus, Diasio Robert B, Largiadèr Carlo R

Zitation

Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038-44.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Clin Cancer Res 2015; 21

Veröffentlichungsdatum

05.02.2015

eISSN (Online)

1557-3265

Seiten

2038-44

Kurzbeschreibung/Zielsetzung

The microRNA miR-27a was recently shown to directly regulate dihydropyrimidine dehydrogenase (DPD), the key enzyme in fluoropyrimidine catabolism. A common polymorphism (rs895819A>G) in the miR-27a genomic region (MIR27A) was associated with reduced DPD activity in healthy volunteers, but the clinical relevance of this effect is still unknown. Here, we assessed the association of MIR27A germline variants with early-onset fluoropyrimidine toxicity.